Liraglutide (Saxenda) for weight loss: what the evidence shows

What did @mari.endocrino actually say?

The transcript provided for this video is, frankly, unusable. What was captured is a string of sign-off phrases and filler speech, not the educational content the caption promises. So we are working primarily from the caption itself, which introduces liraglutide (brand name Saxenda) as a weight-loss injection, credits it with appetite control through the central nervous system, and mentions gastric emptying delay as a mechanism.

The caption states the drug "te ayudará a controlar el apetito, trabajando a nivel del sistema nervioso central y retardando el vaciamiento gástrico" (will help control appetite by working at the level of the central nervous system and delaying gastric emptying). That is a reasonable summary of liraglutide's pharmacology. The creator also teases additional benefits beyond weight loss, which is a legitimate point worth expanding.

Because the actual spoken content was not captured, this fact-check is limited to verifying the caption claims. Anything said in the video itself remains unverified.

Does the science back this up?

On the core mechanism claims, yes, mostly. Liraglutide is a GLP-1 receptor agonist, and its effects on appetite and body weight are well-documented. The dual mechanism described in the caption, central nervous system action and gastric emptying delay, is supported by the evidence, though the relative contribution of each pathway is more nuanced than a short caption can capture.

The CNS component is real. GLP-1 receptors are expressed in the hypothalamus and brainstem, areas involved in satiety signaling. Davies et al. (2015, NEJM) showed that liraglutide 3.0 mg daily produced significantly greater weight loss than placebo in non-diabetic adults with obesity, with appetite reduction as a primary driver. The gastric emptying delay is also documented, though research by Marathe et al. (2013, Diabetes, Obesity and Metabolism) notes this effect may diminish with chronic use, a detail worth flagging. Saxenda's approval by the FDA for chronic weight management in adults came in 2014, and the SCALE trial program provides solid efficacy data across multiple populations.

What did they get wrong (or right)?

The creator gets the basic pharmacology right. Liraglutide does work on GLP-1 receptors in the CNS and does slow gastric emptying. Calling it a weight-loss injection is accurate in the sense that it is a subcutaneous injection, administered daily, approved for weight management.

What is missing, and this is where short-form health content routinely fails people, is context on how it compares to newer agents. Liraglutide is now the older generation of GLP-1 drugs. Semaglutide (Wegovy) demonstrated superior weight loss outcomes in head-to-head context. Rubino et al. (2021, JAMA) reported mean weight reduction of around 14.9% with semaglutide 2.4 mg weekly versus roughly 6% with liraglutide 3.0 mg daily in comparable populations. Presenting Saxenda without acknowledging that more effective options now exist is not wrong, but it is incomplete in a way that could mislead someone making a treatment decision.

The teased "additional benefits" section in the caption is also unverified since the transcript did not capture the spoken content. Claims about cardiovascular benefit, diabetes prevention, or other outcomes should not be assumed accurate without reviewing the actual video.

What should you actually know?

Liraglutide is a legitimate, FDA-approved medication for weight management. It is not a shortcut, and it is not appropriate for everyone. The SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., 2015, NEJM) showed meaningful weight loss at 3.0 mg daily, but also documented that a significant portion of participants regained weight after stopping the drug. This is not a failure of willpower. GLP-1 drugs address a physiological mechanism, and discontinuing them often reverses that effect.

Side effects are real and worth discussing plainly. Nausea, vomiting, and gastrointestinal discomfort are the most common, particularly during dose escalation. Pancreatitis is a rare but documented risk. Thyroid C-cell tumors were observed in rodent studies, which is why liraglutide carries a black box warning and is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN2.

If you are considering any GLP-1 medication, the conversation starts with a licensed clinician who can review your full medical history, not a TikTok caption.